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Abstract
Colonoscopy is a crucial diagnostic instrument for 
colorectal cancer screening and an adequate bowel 
preparation is definitely decisive for the success of the 
procedure. Especially in elderly patients, bowel cleansing 
is considered a big issue, because it is often poorly 
tolerated for many reasons (like inability to swallow large 
volume of liquids or unlikable taste); this can cause a 
suboptimal preparation that may lead to miss a neoplastic 
lesion. There is relatively little data about how to improve 
preparation tolerability. The purpose of our pilot study was 
to analyze the effect of prucalopride (Resolor®), a highly 
selective serotonin 5HT4 receptor agonist used for chronic 
constipation for its ability to stimulate gastrointestinal 
peristalsis, undertaken the day before colonoscopy, 
followed by half volume of polyethylene glycol solution. 
We found that this can be a good and safe method to 
achieve an adequate and better-tolerated colon cleansing. 
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Core tip: Efficacy of bowel cleansing is of crucial 
importance in screening colonoscopies for the prevention 
and early detection of colorectal cancer. Many categories 
of patients however cannot tolerate the large volume of 
liquids that make up standard bowel cleansing regimens. 
Aim of our pilot study was to test the efficacy of pru-
calopride, a highly selective 5HT4 receptor agonist that 
increases bowel movements, in improving bowel cleansing 
and reducing the necessary volume of liquids.
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TO THE EDITOR
Adequacy of preparation is one of the most important 
factors[1] in screening and early detection of colorectal 
cancer (CRC), which still has a high incidence and 
mortality. Poor colon cleansing however still affects 
as many as 20% of colonoscopies, increasing burden 
for patients and total costs of colon cancer screening 
programs[1,2]. Patient tolerability is strongly affected 
by the chosen preparation and manner in which it is 
administered. Many factors have been identified to 
influence bowel preparation such as unappealing taste 
of the solution or inability to swallow large volumes 
of liquids. There have been many efforts to improve 
bowel cleansing like smaller volume solutions, tablets 
consumed with water and split-dose regimens[3,4]. 
Prucalopride, a highly selective serotonin 5HT4 
receptor agonist used for treatment of chronic con-
stipation, stimulates gastrointestinal peristalsis and 
colon movements[5,6]. It is a generally well tolerated 
drug, contraindicated only in patients on dialysis or with 
bowel perforation or obstruction. The most common 
side effects are fatigue, appetite loss, diarrhea and 
headache at first dose administration[5,6]. In the present 
pilot study we tested the hypothesis that a previous 
dose of Prucalopride followed by a low volume of 
polyethylene glycol (PEG) solution, might achieve a 
satisfactory colon cleansing.
A total of 30 consecutive patients, 16F, 14M, mean 
age 55 years (48-62) (complete characteristics ava-
ilable in Table 1), all with regular bowel movements, 
after written informed consent, agreed to use the 
following preparation schedule: on the day before the 
examination, 3 h after a semi-liquid midday meal, 2 mg 
of Prucalopride, and later in the evening, 1 L of PEG-
Asc. solution followed by the assumption of water or 
other clear liquids (> 1 L) (Figure 1). A control group 
of 30 patients with comparable characteristics followed 
the standard 2 L PEG-ASC. Preparation schedule (Figure 
2). All patients underwent colonoscopy either for CRC 
screening or for periodical survey. All had four days of 
low fiber diet and all examinations were performed the 
following morning. The colonoscopies were performed by 
senior endoscopists who were unaware of the preparation 
schedule at the time of the examination. Twelve out of 14 
patients of the Prucalopride group, who were undergoing 
colonoscopy for follow up of previous examinations, 
declared that the new preparation schedule was more 
acceptable compared to the standard one. Specifically, 
none of them reported nausea and/or retching during 
assumption of the PEG-ASC. 
Colonoscopy was completed (caecal intubation) in 
all patients studied. Insertion time is reported in Table 
1. The colon cleansing was rated good/optimal (Boston 
scale 7-9) in 26/30 (87%) and in 25/30 (83%) in study 
and controls group respectively. The adenoma detection 
rate (ADR) among the two groups was comparable (Table 
1). Among patients receiving Prucalopride, two patients 
had mild headache in the following three hours after its 
administration. Among patients receiving standard dose, 
two patients reported nausea and one patient reported 
mild abdominal pain during assumption.
Our pilot study shows that previous Prucalopride 
administration followed by half dose PEG solution 
produced comparable colon cleansing quality than regular 
Table 1  Demographic and anthropometric characteristics n  
(%)
Standard preparation (2 
L PEG-ASC) (n  = 30)
Prucalopride + 1 L 
PEG-ASC (n  = 30)
Age median (range) 53 (46-67) 55 (48-64)
Sex   14 (47) 14 (47)
BMI median (range)   26.7 (18.4-32.8) 25.4 (17.3-31)
Boston scale ≥ 7 26 (87) 25 (83)
Boston scale ≤ 6 4   (13) 5   (17)
Exam indication
  Screening 18 (60) 16 (53)
  Follow up 12 (40) 14 (47)
Adenoma detection 
rate (%)
32 29
Time to preparation 
(h) median (range)
    11.30 (10.45-12.30)      11.45 (10.30-12.45)
Colonoscopy 
insertion time (min), 
median (range)
8.2 (3.3-36) 7.6 (3.1-47)
Semiliquid lunch                    Prucalopride 2 mg                1 It Peg Asc. solution                      Colonoscopy
h 15:00                                h 18:00                                h 20:00                                    h 9:00 
Figure 1  Time scale of Prucalopride preparation scheme.
Semiliquid lunch             1 It Peg Asc. solution                1 It Peg Asc. solution                  Colonoscopy
h 15:00                                h 18:00                                h 20:00                                    h 9:00 
Figure 2  Time scale of standard preparation scheme.
PEG: Polyethylene glycol; BMI: Body mass index.
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standard dose. Faster intestinal transit with intestinal 
residuals removal stimulated by previous Prucalopride 
administration might explain why a reduced volume of 
preparation solution could achieve a satisfactory bowel 
cleansing. These results must be further investigated by 
a wider, prospective, randomized control trial that can 
confirm these preliminary findings and facilitate colon 
cleansing for those patients that are unable to drink large 
volumes of liquid.
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